<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35226248</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-0283</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell biochemistry and biophysics</Title>
          <ISOAbbreviation>Cell Biochem Biophys</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bisphosphonate of Zoledronate Has Antiapoptotic Effect on Hypoxia/Reoxygenation Injury in Human Embryonic Stem Cell-Derived Cardiomyocytes Through Trk Signaling Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>435</StartPage>
          <EndPage>442</EndPage>
          <MedlinePgn>435-442</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12013-021-01031-7</ELocationID>
        <Abstract>
          <AbstractText>In this work, we investigated the in vitro and in vivo functions of bisphosphonate of zoledronate (Zd) in hypoxia/reoxygenation (H/R) injured human embryonic stem cell-derived cardiomyocytes (hES-CMs). In the in vitro setting, the effects of Zd on hES-CM survival and differentiation were examined. We found that low and medium concentrations (&lt;2 µm) of Zd did not induce cell death of hES-CMs. 0.5 µm Zd protected H/R-induced hES-CM apoptosis but did not affect key differentiation proteins, including hcTnl, PECM-1 Cnx43 and Pan-Cadherin. In addition, Zd-induced TrkA/B phosphorylation and promoted VEGF to counter the apoptotic effect of H/R injury. In the in vivo animal model of myocardial infarction, Zd treatment promoted the survival of hES-CMs by inducing PECAM1 and hcTnl. Thus, we concluded that Zd protected H/R-induced hES-CM apoptosis in vitro and promoted hES-CM survival in vivo. These data may facilitate the development of human embryonic stem cells into clinical applications for patients with ischemic heart disease.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-7311-4576</Identifier>
            <AffiliationInfo>
              <Affiliation>Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhao</LastName>
            <ForeName>Wen-Shu</ForeName>
            <Initials>WS</Initials>
            <Identifier Source="ORCID">0000-0002-7552-2984</Identifier>
            <AffiliationInfo>
              <Affiliation>Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-9096-5062</Identifier>
            <AffiliationInfo>
              <Affiliation>Heart Center and Beijing Key Laboratory of Hypertension Research, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. lxdrqw09_dr@aol.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Biochem Biophys</MedlineTA>
        <NlmUniqueID>9701934</NlmUniqueID>
        <ISSNLinking>1085-9195</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6XC1PAD3KF</RegistryNumber>
          <NameOfSubstance UI="D000077211">Zoledronic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000066449" MajorTopicYN="Y">Human Embryonic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="Y">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077211" MajorTopicYN="N">Zoledronic Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Human embryonic stem cell</Keyword>
        <Keyword MajorTopicYN="N">Ischemia</Keyword>
        <Keyword MajorTopicYN="N">Myocardial infarction</Keyword>
        <Keyword MajorTopicYN="N">Reoxygenation</Keyword>
        <Keyword MajorTopicYN="N">Reperfusion</Keyword>
        <Keyword MajorTopicYN="N">Zoledronate</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35226248</ArticleId>
        <ArticleId IdType="doi">10.1007/s12013-021-01031-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s12013-021-01031-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Heusch, G., Libby, P., Gersh, B., Yellon, D., Bohm, M., Lopaschuk, G., &amp; Opie, L. (2014). Cardiovascular remodelling in coronary artery disease and heart failure. Lancet, 383(9932), 1933–1943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)60107-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lippi, G., Franchini, M. &amp; &amp; Cervellin, G. (2013). Diagnosis and management of ischemic heart disease. Seminars in Thrombosis and Hemostasis, 39(2), 202–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1333543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boateng, S., &amp; Sanborn, T. (2013). Acute myocardial infarction. Disease-A-Month, 59(3), 83–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.disamonth.2012.12.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welch, T. D., Yang, E. H., Reeder, G. S. &amp; &amp; Gersh, B. J. (2012). Modern management of acute myocardial infarction. Current Problems in Cardiology, 37(7), 237–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cpcardiol.2012.03.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minicucci, M. F., Azevedo, P. S., Polegato, B. F., Paiva, S. A., &amp; Zornoff, L. A. (2011). Heart failure after myocardial infarction: clinical implications and treatment. Clinical Cardiology, 34(7), 410–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/clc.20922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widgerow, A. D. (2014). Ischemia-reperfusion injury: influencing the microcirculatory and cellular environment. Annals of Plastic Surgery, 72(2), 253–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SAP.0b013e31825c089c</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausenloy, D. J., &amp; Yellon, D. M. (2013). Myocardial ischemia-reperfusion injury: a neglected therapeutic target. Journal of Clin Investigation, 123(1), 92–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI62874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kennedy-Lydon, T., &amp; Rosenthal, N. (2015). Cardiac regeneration: epicardial mediated repair. Proceedings of the Royal Society B: Biological Sciences, 282(1821), 20152147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1098/rspb.2015.2147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta, A., &amp; Shim, W. (2013). Cardiac stem cell therapy: stemness or commitment? Cell Transplantation, 22(1), 1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3727/096368912X653282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young, P. P., &amp; Schafer, R. (2015). Cell-based therapies for cardiac disease: a cellular therapist’s perspective. Transfusion, 55(2), 441–451. quiz 440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/trf.12826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beqqali, A., van Eldik, W., Mummery, C. &amp; &amp; Passier, R. (2009). Human stem cells as a model for cardiac differentiation and disease. Cellular and Molecular Life Sciences, 66(5), 800–813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-009-8476-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nir, S. G., David, R., Zaruba, M., Franz, W. M., &amp; Itskovitz-Eldor, J. (2003). Human embryonic stem cells for cardiovascular repair. Cardiovascular Research, 58(2), 313–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0008-6363(03)00264-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acimovic, I., Vilotic, A., Pesl, M., Lacampagne, A., Dvorak, P., Rotrekl, V., &amp; Meli, A. C. (2014). Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools. Biomedical Research International, 2014, 512831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/512831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laflamme, M. A., Chen, K. Y., Naumova, A. V., Muskheli, V., Fugate, J. A., Dupras, S. K., Reinecke, H., Xu, C., Hassanipour, M., &amp; Police, S., et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25(9), 1015–1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terrovitis, J. V., Smith, R. R., &amp; Marban, E. (2010). Assessment and optimization of cell engraftment after transplantation into the heart. Circulation Research, 106(3), 479–494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.109.208991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caspi, O., Huber, I., Kehat, I., Habib, M., Arbel, G., Gepstein, A., Yankelson, L., Aronson, D., Beyar, R., &amp; Gepstein, L. (2007). Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of American College of Cardiology, 50(19), 1884–1893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2007.07.054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henning, R. J. (2011). Stem cells in cardiac repair. Future Cardiology, 7(1), 99–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fca.10.109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bock, O., &amp; Felsenberg, D. (2008). Bisphosphonates in the management of postmenopausal osteoporosis–optimizing efficacy in clinical practice. Clinical Interventions in Aging, 3(2), 279–297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CIA.S2134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman, R. E. (2004). Bisphosphonates: clinical experience. Oncologist, 9(Suppl 4), 14–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.9-90004-14</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, G. D., Mundy, G. R., &amp; Boyce, B. F. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone Mineral Research, 10(10), 1478–1487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbmr.5650101008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleisch, H. (1989). Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results in Cancer Research, 116, 1–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-642-83668-8_1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watts, N. B. &amp; &amp; Diab, D. L. (2010). Long-term use of bisphosphonates in osteoporosis. The Journal of Clinical Endocrinology and Metabolism, 95(4), 1555–1565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-1947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai, S. H., Huang, P. H., Chang, W. C., Tsai, H. Y., Lin, C. P., Leu, H. B., Wu, T. C., Chen, J. W., &amp; Lin, S. J. (2012). Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PLoS One, 7(7), e41065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0041065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seist, R., Tong, M., Landegger, L. D., Vasilijic, S., Hyakusoku, H., Katsumi, S., McKenna, C. E., Edge, A. S. B., &amp; Stankovic, K. M. (2020). Regeneration of cochlear synapses by systemic administration of a bisphosphonate. Frontiers in Molecular Neuroscience, 13, 87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2020.00087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guide for the Care and Use of Laboratory Animals. edn. Washington (DC); 1996.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhu, W. Z., Van Biber, B., &amp; Laflamme, M. A. (2011). Methods for the derivation and use of cardiomyocytes from human pluripotent stem cells. Methods in Molecular Biology, 767, 419–431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-61779-201-4_31</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh, A., Feric, N. T., &amp; Radisic, M. (2015). Combined hypoxia and sodium nitrite pretreatment for cardiomyocyte protection in vitro. Biotechnology Progess, 31(2), 482–492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/btpr.2039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo, J., Weaver, M. S., Cao, B., Dennis, J. E., Van Biber, B., Laflamme, M. A., &amp; Allen, M. D. (2014). Cobalt protoporphyrin pretreatment protects human embryonic stem cell-derived cardiomyocytes from hypoxia/reoxygenation injury in vitro and increases graft size and vascularization in vivo. Stem Cells Translational Medicine, 3(6), 734–744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5966/sctm.2013-0189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, H. C., Zhang, H. F., Guo, W. Y., Su, H., Zhang, K. R., Li, Q. X., Yan, W., Ma, X. L., Lopez, B. L., &amp; Christopher, T. A., et al. (2006). Hypoxic postconditioning enhances the survival and inhibits apoptosis of cardiomyocytes following reoxygenation: role of peroxynitrite formation. Apoptosis, 11(8), 1453–1460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-006-7786-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai, J., Yi, F. F., Yang, X. C., Lin, G. S., Jiang, H., Wang, T., &amp; Xia, Z. (2007). Transplantation of embryonic stem cell-derived cardiomyocytes improves cardiac function in infarcted rat hearts. Cytotherapy, 9(3), 283–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14653240701247838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huwer, H., Winning, J., Vollmar, B., Welter, C., Lohbach, C., Menger, M. D., &amp; Schafers, H. J. (2003). Long-term cell survival and hemodynamic improvements after neonatal cardiomyocyte and satellite cell transplantation into healed myocardial cryoinfarcted lesions in rats. Cell Transplantation, 12(7), 757–767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3727/000000003108747361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fazmin, IT, Huang, CL, Jeevaratnam, K. Bisphosphonates and atrial fibrillation: revisiting the controversy. Annals of the New York Academy of Sciences, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Loke, Y. K., Jeevanantham, V., &amp; Singh, S. (2009). Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Safety, 32(3), 219–228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00002018-200932030-00004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arslan, C., Aksoy, S., Dizdar, O., Dede, D. S., Harputluoglu, H., &amp; Altundag, K. (2011). Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer, 19(3), 425–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00520-010-0868-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilgezdi, Z. D., Aktas, I., Dogan Metin, F., Kepez, A., Unlu Ozkan, F., Silte, A. D., Yilmaz Kaysin, M., Kivrak, T., Cincin, A., &amp; Erdogan, O. (2015). Acute effect of zoledronic acid infusion on atrial fibrillation development in patients with osteoporosis. The Anatolian Journal of Cardiology, 15(4), 320–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5152/akd.2014.5333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, Z., Wang, S. P., Shao, Q., Li, P. F., Sun, Y., Luo, L. Z., Yan, X. Q., Fan, Z. Y., Hu, J. &amp; &amp; Zhao, J. et al. (2019). Brain-derived neurotrophic factor mimetic, 7,8-dihydroxyflavone, protects against myocardial ischemia by rebalancing optic atrophy 1 processing. Free Radical Biology and Medicine, 145, 187–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2019.09.033</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
